Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.

Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA.

JAMA. 2007 Dec 12;298(22):2634-43.

PMID:
18073359
2.

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative..

Ann Intern Med. 2007 Oct 16;147(8):573-7. Erratum in: Ann Intern Med. 2008 Jan 15;148(2):168.

PMID:
17938396
3.

Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information.

Stürmer T, Glynn RJ, Rothman KJ, Avorn J, Schneeweiss S.

Med Care. 2007 Oct;45(10 Supl 2):S158-65. Review.

4.

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

Singh S, Loke YK, Furberg CD.

JAMA. 2007 Sep 12;298(10):1189-95.

PMID:
17848653
5.
6.

Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus.

Türkmen Kemal Y, Güvener Demirag N, Yildirir A, Atar A, Dogruk Unal A, Biyiklioglu Z.

Acta Diabetol. 2007 Sep;44(3):149-56. Epub 2007 Aug 26.

PMID:
17721754
7.

Rosiglitazone and cardiotoxicity--weighing the evidence.

Nathan DM.

N Engl J Med. 2007 Jul 5;357(1):64-6. Epub 2007 Jun 5. No abstract available.

8.

Thiazolidinediones and heart failure: a teleo-analysis.

Singh S, Loke YK, Furberg CD.

Diabetes Care. 2007 Aug;30(8):2148-53. Epub 2007 May 29.

PMID:
17536074
9.

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Nissen SE, Wolski K.

N Engl J Med. 2007 Jun 14;356(24):2457-71. Epub 2007 May 21. Erratum in: N Engl J Med. 2007 Jul 5;357(1):100..

10.

Racial disparities in the prevalence of cardiovascular disease among incident end-stage renal disease patients.

Volkova N, McClellan W, Soucie JM, Schoolwerth A.

Nephrol Dial Transplant. 2006 Aug;21(8):2202-9. Epub 2006 Mar 7.

PMID:
16522661
11.

Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.

Hartung DM, Touchette DR, Bultemeier NC, Haxby DG.

Pharmacotherapy. 2005 Oct;25(10):1329-36.

PMID:
16185176
12.

The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease.

Sachdev M, Sun JL, Tsiatis AA, Nelson CL, Mark DB, Jollis JG.

J Am Coll Cardiol. 2004 Feb 18;43(4):576-82.

13.

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study.

Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS.

Diabetes Care. 2003 Nov;26(11):2983-9.

PMID:
14578227
14.
16.

Estimating causal effects from large data sets using propensity scores.

Rubin DB.

Ann Intern Med. 1997 Oct 15;127(8 Pt 2):757-63. Review.

PMID:
9382394

Supplemental Content

Support Center